ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6 is on this study

  • The record lists it as a treatment, written “INT230-6”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 1, 2026, 8:22 AM UTC
  • The role rule says the same.
  • So Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6's page lists this study under “Testing it”.
17 links1 made here, not in the record21 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govMade here
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT03058289A Phase 1/2 Safety Study ofIntratumorally DosedINT230-6Intensity Therapeutics, Inc.Phase 1/Phase 2 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSBreast NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionHead and Neck NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseCarcinoma, Squamous CellThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseLymphomaThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseasePancreatic NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termLiver NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termColonic NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termLung NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termBile Duct NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Finest filed termFinest filed termSarcomaThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseNeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDiabetes Mellitus, Insulin-…The registry's MeSH filing›Nov 14 · Rule based · MisfiledMisfiledCarcinomaThe registry's MeSH filing›Nov 14 · Rule based · General: a category, not a diseaseGeneral: a category, not a diseaseDRUGSCisplatin/Vinblastine/Cell …Entry “INT230-6”, read by our name ru…›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedImmune checkpoint inhibitorsEntry “anti-PD-1 antibody”, read by o…›Nov 1 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundIpilimumabEntry “anti-CTLA-4 antibody”, read by…›Nov 1 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · BackgroundBackground · partnerPembrolizumabMade here · Found by reading; no entr…›Nov 1 · Claude Opus 5.5 · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6Claude Opus 5.5TestedCurrent
Nov 1Immune checkpoint inhibitorsClaude Opus 5.5BackgroundCurrent
Nov 1IpilimumabClaude Opus 5.5Background · partnerCurrent
Nov 1Pembrolizumabmade hereClaude Opus 5.5BackgroundCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 14Breast NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Head and Neck NeoplasmsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Carcinoma, Squamous CellRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14LymphomaRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Pancreatic NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Liver NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Colonic NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Lung NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14Bile Duct NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 14SarcomaRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14NeoplasmsRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 14Diabetes Mellitus, Insulin-Dependent, 12Rule based · condition-kind ruleMisfiledCurrent
Nov 14CarcinomaRule based · condition-kind ruleGeneral: a category, not a diseaseCurrent
Nov 18Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6Rule based · role ruleTestedAgrees
Nov 18Immune checkpoint inhibitorsRule based · role ruleBackgroundAgrees
Nov 18IpilimumabRule based · role ruleBackgroundAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.